Medscape
The US Food and Drug Administration (FDA) has approved Avadel Pharmaceuticals’ supplemental new drug application for extended-release sodium oxybate (Lumryz) for treatment of cataplexy or excessive daytime sleepiness in children 7 years of age and older with narcolepsy. The FDA first approved the once-nightly formulation of sodium oxybate for treatment of cataplexy or excessive daytime …
Read More
FDA OKs Once-Nightly Lumryz for Children With Narcolepsy
Arden Antes
23:32
The US Food and Drug Administration (FDA) has approved Avadel Pharmaceuticals’ supplemental new drug application for extended-release sodium oxybate (Lumryz) for treatment of cataplexy or excessive daytime sleepiness in children 7 years of age and older with narcolepsy. The FDA first approved the once-nightly formulation of sodium oxybate for treatment of cataplexy or excessive daytime
